Genetically engineered mouse models of ovarian cancer and their utility in drug discovery

Current Protocols in Pharmacology

Volumn , Issue SUPPL. 45, 2009, Pages

  Šale, Sanja ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Ad CRE; Epithelial ovarian cancer (EOC); Genetically engineered mouse models (GEMMs); Ovarian surface epithelium (OSE); RCAS TVA gene delivery system; Specific genetic lesions

Indexed keywords

K RAS PROTEIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; RETROVIRUS VECTOR; TUMOR MARKER; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ASCITES; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; EPITHELIAL OVARY CANCER; EPITHELIUM CELL; EXPERIMENTAL MODEL; FEMALE; GENETIC ENGINEERING; MOUSE; NONHUMAN; OVARY CANCER; OVARY SURFACE EPITHELIA; PRIORITY JOURNAL; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SPECIMEN HANDLING;

EID: 84859432041     PISSN: 19348282     EISSN: 19348290     Source Type: Journal    
DOI: 10.1002/0471141755.ph1411s45     Document Type: Review

References (40)

1. Andrechek, E.R., White, D., and Muller, W.J. 2005. Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth. Oncogene 24:932-937.
2. Ashworth, A., Balkwill, F., Bast, R.C., Berek, J.S., Kaye, A., Boyd, J.A.,Mills, G., Weinstein, J.N., Woolley, K., and Workman, P. 2008. Opportunities and challenges in ovarian cancer research, a perspective from the 11th ovarian cancer action/HHMT forum, Lake Como, March 2007. Gynecol. Oncol. 3:652-657.
3. Aunoble, B., Sanches, R., Didier, E., and Bignon, Y. 2000. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. Intl. J. Oncol. 16:567-576.
4. Auersperg, N., Wong, A.S., Choi, K.C., Kang, S.K., and Leung, P.C. 2001. Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocr. Rev. 22:255-288.
5. Bates, P., Young, J.A., and Varmus, H.E. 1993. A receptor for subgroup A Rous sarcoma virus is related to the low density lipoprotein receptor. Cell 74:1043-1051.
6. Bhaskar, P.T. and Hay, N. 2007. The two TORCs and Akt. Dev. Cell 12:487-502.
7. Cheng, W., Liu, J., Yoshida, H., Rosen, D., and Naora, H. 2005. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat. Med. 5:531-537.
8. Connolly, D.C., Bao, R., Nikitin, A.Y., Stephens, K.C., Poole, T.W., Hua, X., Harris, S.S., Vanderhyden, B.C., and Hamilton, T.C. 2003. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 6:1389-1397.
9. Dinulescu, D.M., Ince, T.A., Quade, B.J., Shafer, S.A., Crowley, D., and Jacks, T. 2005. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 1:63-70.
10. Feeley, K.M. and Wells, M. 2001. Precursor lesions of ovarian epithelial malignancy. Histopathology 38:87-95.
11. Fingar, D.C. and Blenis, J. 2004. Target of Rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151-3171.
12. Flesken-Nikitin, A., Choi, K.C., Eng, J.P., Shmidt, E.N., and Nikitin, A.Y. 2003. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 63:3459-3463.
13. Garson, K., Shaw, T.J., Clark, K.V., Yao, D.S., and Vanderhyden, B.C. 2005. Models of ovarian cancer - are we there yet? Mol. Cell. Endocrinol. 239:15-26.
14. Gregson, R.L., Lewis, D.J., and Abbott, D.P. 1984. Spontaneous ovarian neoplasms of the laboratory rat. Vet. Pathol. 21:292-299.
15. Gu, H., Zou, Y.R., and Rajewsky, K. 1993. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 6:1155-1164.
16. Hoffman, R.M. 1999. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: A bridge to the clinic. Invest. New Drugs 4:343-359.
17. Hughes, S.H., Greenhouse, J.J., Petropoulos, C.J., and Sutrave, P. 1987. Adaptor plasmids simplify the insertion of foreign DNA into helper independent retroviral vectors. J. Virol. 61:3004-3012.
18. Jackson, E.L., Willis, N., Mercer, K., Bronson, R.T., Crowley, D., Montoya, R., Jacks, T., and Tuveson, D.A. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15:3243-3248.
19. Khanna, C. and Hunter, K. 2005. Modeling metastasis in vivo. Carcinogenesis 3:513-523.
20. Lakso, M., Sauer, B., Mosinger, B. Jr., Lee, E.J., Manning, R.W., Yu, S.H., Mulder, K.L., and Westphal, H. 1992. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 14:6232-6236.
21. Landen Jr., C.N., Birrer, M.J., and Sood, A.K. 2008. Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol. 26:995-1005.
22. Manning, B.D. and Cantley, L.C. 2007. AKT/PKB signaling: Navigating downstream. Cell 129:1261-1274.
23. Orban, P.C., Chui, D., and Marth, J.D. 1992. Tissue- and site-specific DNA recombination in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 15:6861-6865.
24. Orsulic, S. 2004. Ovarian cancer. In Mouse Models of Human Cancer. (E.C. Holland, ed.) pp. 171-185. John Wiley & Sons, Inc.
25. Orsulic, S., Li, Y., Soslow, R.A., Vitale-Cross, L.A., Gutkind, J.S., and Varmus, H.E. 2002. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1:53-62.
26. Ozols, R.F., Bookman, M.A., Connolly, D.C., Daly, M.B., Godwin, A.K., Schilder, R.J., Xu, X., and Hamilton, T.C. 2004. Focus on epithelial ovarian cancer. Cancer Cell 1:19-24.
27. Purdie, D.M., Webb, PM, Siskind, V., Bain, C.J., and Green, A.C. 2003. The different etiologies ofmucinous and nonmucinous epithelial ovarian cancers. Gynecol. Oncol. 88:S145-S148.
28. Sahai, E. 2007. Illuminating the metastatic process. Nat. Rev. Cancer 7:737-749.
29. Sale, S. and Orsulic, S. 2006. Models of ovarian cancer metastasis: Murine models. Drug Discov. Today 2006. 3:149-154.
30. Sankaranarayanan, R. and Ferlay, J. 2006. Worldwide burden of gynaecological cancer: The size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol. 2:207-225.
31. Sauer, B. 1993. Manipulation of transgenes by sitespecific recombination: Use of Cre recombinase. Methods Enzymol. 225:890-900.
32. Sausville, E.A. and Burger, A.M. 2006. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 7:3351-3354.
33. Shaw, T.J., Senterman, M.K., Dawson, K., Crane, C.A., and Vanderhyden, B.C. 2004. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Ther. 6:1032-1042.
34. Shih, I.M. and Kurman, R.J. 2004. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 164:1511-1518.
35. Singh, M. and Johnson, L. 2006. Using genetically engineered mouse models of cancer to aid drug development: An industry perspective. Clin. Cancer Res. 18:5312-5328.
36. Vanderhyden, B.C., Shaw, T.J., and Ethier, J.F. 2003. Animal models of ovarian cancer. Reprod. Biol. Endocrinol. 1:67.
37. Wang, Y., Krushel, L.A., and Edelman, G.M. 1996. Targeted DNA recombination in vivo using an adenovirus carrying the cre recombinase gene. Proc. Natl. Acad. Sci. U.S.A. 9:3932-3936.
38. Wu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D.R., Akyol, A., Hanash, S., Misek, D.E., Katabuchi, H., Williams, B.O., Fearon, E.R., and Cho, K.R. 2007. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/betacatenin and PI3K/ Pten signaling pathways. Cancer Cell 4:321-333.
39. Xing, D. and Orsulic, S. 2005. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc. Natl. Acad. Sci. U.S.A. 102:6936-6941.
40. Young, J.A., Bates, P. and Varmus, H.E. 1993. Isolation of a chicken gene that confers susceptibility to infection by subgroup A avian leukosis and sarcoma viruses. J. Virol. 67:1811-1816.